About Marinomed
Marinomed is a publicly listed company based in Vienna (Austria) founded in 2006 by Eva Prieschl-Grassauer and Andreas Grassauer. Drugs for immunology, allergy, and infectious diseases are developed. Its chief executive, as recorded, is Andreas Grassauer. Marinomed offers products and services including Carragelose eye drops. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is Marinomed Biotech AG.
Company details
Founded in 2006 and based in Vienna, Austria, the company focuses on biotechnology in immunology, allergy, and infectious diseases. Patent-protected products are developed using the Marinosolv platform, which enhances solubility and bioavailability of poorly soluble compounds for treating autoreactive immune disorders. Virus-blocking properties of iota-carrageenan are utilized in virology applications. Operations center on therapeutic innovation in these sectors.
- Headquarters Vienna, Austria
- Founders Eva Prieschl-Grassauer, Andreas Grassauer
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website marinomed.com/en
- Social LinkedIn X
- Legal Name Marinomed Biotech Ag
- Latest Funding Round$6.27M (USD), Post-IPO
Oct 2021
- InvestorsNice & Green
& 2 more
Products & Services of Marinomed
Marinomed offers a comprehensive portfolio of products and services, including Carragelose eye drops.
Eye drops for treating dry eyes associated with viral conditions.
Funding Insights of Marinomed
- Total Rounds 3
- Last Round Post-IPO — $6.27M
- Investors Count 3
All 3 funding rounds of Marinomed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2021 | $6.27M | Post-IPO | – | – | |
| May 2016 | Private Equity Round | – | Invest | – | |
| Oct 2015 | Series A | – | aws Mittelstandsfonds | – |
3 investors in total: 3 institutional.
Investors in Marinomed
Marinomed has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Nice & Green, Invest and Mittelstandsfonds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| investag.at | ||||
Growth capital is provided to mid-sized companies in Austria. | mittelstands-fonds.at | Austria | ||
Finance services are provided by Nice & Green in Switzerland. | 2017 | nicengreen.ch | Nyon, Switzerland |
Investor details for Marinomed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Marinomed
2 people are tracked at Marinomed (2 in leadership).
| Name | Role | Group |
|---|---|---|
Eva Prieschl-Grassauer | Co-Founder | Leadership |
Andreas Grassauer | Co-Founder & CEO | Leadership |
Complete people profiles for Marinomed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Marinomed
4 dated milestones of Marinomed across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Marinomed is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $6.3M.
Web traffic of Marinomed
The website of Marinomed (marinomed.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 2867.7% vs previous month
Websites whose visitors overlap most with Marinomed. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
onlineapo.at | onlineapo.at | 100% | #337,038 | – | |
| apothekenbote.at | 88% | #801,049 | View details | ||
farmaciiledona.ro | farmaciiledona.ro | 84% | #2,234,869 | – | |
vamida.at | vamida.at | 78% | #257,537 | – | |
sanafarm.ro | sanafarm.ro | 78% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Marinomed
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Marinomed
Complete news archive for Marinomed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Marinomed
Marinomed was founded in 2006 and raised its 1st funding round 9 years after it was founded.
Marinomed is headquartered in Vienna, Austria.
Andreas Grassauer is the CEO of Marinomed, as recorded in our data. They have also founded this company.
Founded in 2006 and based in Vienna, Austria, the company focuses on biotechnology in immunology, allergy, and infectious diseases. Patent-protected products are developed using the Marinosolv platform, which enhances solubility and bioavailability of poorly soluble compounds for treating autoreactive immune disorders. Virus-blocking properties of iota-carrageenan are utilized in virology applications. Operations center on therapeutic innovation in these sectors.
Marinomed offers Carragelose eye drops.
Marinomed has 3 investors. Key investors include Nice & Green, Invest, and Mittelstandsfonds.
Marinomed operates through Marinomed Biotech Ag.